Sign in

CIK 0001528172 · Non-accelerated filer<br>Smaller reporting company

ENDONOVO THERAPEUTICS, INC.

Sign in to watch
Ticker
ENDV
Exchange
OTC
Industry
Electromedical & Electrotherapeutic Apparatus
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
452552528
Phone
(800) 489-4774
Business address
6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS, CA, 91367
Former names
Hanover Portfolio Acquisitions, Inc.
  1. 4 Open-market buy President bought 56,000 shares at an average $0.02 ($1,151)
  2. 4 Open-market buy CEO bought 103,500 shares at an average $0.02 ($2,040)
  3. 4 Open-market buy CEO bought 46,500 shares at an average $0.02 ($966)
  4. 4 Open-market buy CEO bought 40,000 shares at an average $0.02 ($889)
  5. 4 Open-market buy CEO bought 50,000 shares at an average $0.02 ($1,159)
  6. 4 Open-market buy CEO bought 17,000 shares at an average $0.02 ($389)
  7. 4 Open-market buy CEO bought 174,000 shares at an average $0.02 ($3,932)
  8. 4 Open-market buy CEO bought 17,500 shares at $0.02 ($390)
  9. 4 Open-market buy CEO bought 213,000 shares at an average $0.02 ($4,807)
  10. EFFECT Other Notice of Effectiveness
  11. 4 Open-market buy CEO bought 38,000 shares at an average $0.03 ($985)
  12. UPLOAD Other SEC-generated Letter
  13. 4 Open-market buy President bought 4,000 shares at $0.03 ($103)
  14. CORRESP Other Correspondence Between Filers and SEC Staff
  15. 4 Open-market buy CEO bought 46,000 shares at an average $0.03 ($1,188)
  16. 4 Open-market buy CEO bought 59,000 shares at an average $0.03 ($1,696)
  17. 4 Open-market buy CEO bought 120,500 shares at an average $0.03 ($3,306)
  18. 4 Open-market buy President bought 10,000 shares at an average $0.03 ($276)
  19. 4 Open-market buy CEO bought 65,500 shares at an average $0.03 ($1,774)
  20. 4 Open-market buy CEO bought 161,500 shares at an average $0.03 ($5,056)

Page 7 of 26 · 502 filings